Robin Bhattacherjee BSc (Hons) joined Actimed Therapeutics as CEO in August 2019. Robin was previously with Actelion from 2009 and was the General Manager for the UK and Ireland Affiliate and a member of the European Management Team.
Robin served on the ABPI Board of Management from 2011 – 2017 as one of the elected Small Companies Group representatives, with a particular interest in medicines that come under specialised commissioning. Prior to Actelion, Robin was the General Manager for CV Therapeutics Europe (CVT) from 2004 to mid-2009, prior to the acquisition of the Company by Gilead. Responsibilities included delivering the European licencing and pre-marketing objectives for the product portfolio and the build and management of European affiliates. He also played a major role in successful European business development activities. Robin joined CVT from Sanofi-Synthélabo UK, where he was Head of Marketing and he also sat on the Irbesartan Global Strategy Team.
From 1986 to 2002, Robin held a variety of positions at Bayer including Marketing Manager and National Sales Manager in the UK and he was a Director in Bayer’s Global Strategic Marketing Group. During his career, Robin has been involved in several product launches both in the UK and Europe. Robin grew up in the North West of England and has an honours degree in Biological Sciences gained at University of London.
Frank Misselwitz, Chief Medical Officer and Non-executive Director
Frank Misselwitz MD, PhD, is Actimed’s Chief Medical Officer. He joined the Company from Bayer AG, where he was Corporate Vice President and Therapeutic Area Head in clinical development. With a background in academia and industry, he has over 30 years extensive pharmaceutical industry experience. Frank supported the development of Humira ($20billion in 2018) at Knoll AG and Abbott and has completed development of multiple cardiovascular drugs (including rivaroxaban). Frank is a member of Scientific Advisory Board of the German Center for Cardiovascular Research and the Centre for Thrombosis and Haemostasis University of Mainz Germany; he has extensive clinical research experience including the landmark COMPASS trial. His previous academic research experience was gained in UK, USA, Germany and Russia and he is the author of over 250 publications, has a cumulated impact factor of 1200 and a Hirsch-Index of 67.
Elaine Morten, Head of Regulatory Affairs and Technical Development
Elaine Morten, PhD began working with Actimed in 2017 as a consultant before joining the Company in 2022. Elaine brings over 25 years of global drug development experience to Actimed predominantly obtained in small to mid-size organisations. Elaine has a track record of taking products through development to marketing authorisation and beyond and has diverse therapeutic and territorial experience. Prior to joining Actimed, Elaine was an independent consultant to the Pharmaceutical Industry and before this, she was Vice President of Regulatory Affairs and Head of Pharmacovigilance at The Medicines Company. Elaine has also worked for British Biotech as Head of Regulatory Affairs and Shire Pharmaceuticals as Regulatory Affairs Manager.
Louise Bosworth, Head of Clinical Operations and Quality
Louise Bosworth is the Head of Clinical Operations and Quality for Actimed, responsible for leading the Clinical Operations Strategy and delivering the Clinical Development Programme. With over 25 years of Clinical Development and Quality experience in the pharmaceutical industry, Louise joined Actimed in September 2021. Louise has held senior positions at large pharma companies including Eli Lilly & Company and Amgen as well as smaller biopharma companies, GW Pharma and Orphalan. Louise has also worked for the leading Clinical Research Organisation IQVIA. Louise’s extensive quality experience includes establishing Quality Management Systems, leading both local and international inspection readiness programs as well as regulatory inspections. Her broad therapeutic and management responsibilities incorporate Clinical and Quality expertise across the industry including fields of oncology and rare diseases products.
Jane Costello, Quality Manager
Jane Costello joined Actimed Therapeutics in 2022, and as acting Quality Manager Jane’s responsibilities include managing the Company’s auditing and quality systems. With over 20 years of industry knowledge, Jane joins the company with experience in clinical research and quality assurance as well as the introduction and management of quality management systems and support of pharmaceutical companies with Regulatory Authority inspections.
Jane founded Netherton QA Consultancy in 2005, a Quality Assurance company offering global support, development, and management to small and large pharma companies. As a Quality Consultant, Jane has worked with a variety of long-standing clients including Chroma Therapeutics Ltd and Kyowa Hakko Kirin, where she has undertaken central management responsibilities and assisted in a succession of positive Regulatory Authority inspections. Prior to this, Jane spent 8 years working with the Oxford Blood Transfusion Service where she specialised in Blood Group Serology and Haematology and 12 years at a leading UK biotech company where she progressed with the company in numerous roles, including Quality Assurance Technical Officer.